Similar findings were observed in TRIAD, where plasma p-tau217 outperformed hippocampal atrophy (AUC, 0.70; 95% CI, 0.63-0.76; P < .001) and tau PET (AUC, 0.86; 95% CI, 0.82-0.91; P = .05) for detecting abnormal Aβ pathology but did not significantly differ from various CSF biomarkers (eFigure 5B in Supplement 1). This evidence concerns the gene MAPT and hippocampal atrophy.